2-year safety and efficacy results for benralizumab

被引：4
|
作者：
Chung, Kian Fan [1 ,2 ]
机构：
[1] Imperial Coll London, Natl Heart & Lung Inst, Fac Med, London SW3 6LY, England
[2] Royal Brompton & Harefield NHS Fdn Trust, Resp Unit, London, England
来源：
LANCET RESPIRATORY MEDICINE | 2019年 / 7卷 / 01期
关键词：
SEVERE ASTHMA;
D O I：
10.1016/S2213-2600(18)30468-5
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：5 / 6
页数：3
相关论文
共 50 条
  • [1] Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
    Braun, Juergen
    Kiltz, Uta
    Deodhar, Atul
    Tomita, Tetsuya
    Dougados, Maxime
    Bolce, Rebecca
    Sandoval, David
    Lin, Chen-Yen
    Walsh, Jessica
    RMD OPEN, 2022, 8 (02):
  • [2] Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results
    Maniatis, Aristides K.
    Casella, Samuel J.
    Nadgir, Ulhas M.
    Hofman, Paul L.
    Saenger, Paul
    Chertock, Elena D.
    Aghajanova, Elena M.
    Korpal-Szczyrska, Maria
    Vlachopapadopoulou, Elpis
    Malievskiy, Oleg
    Chaychenko, Tetyana
    Cappa, Marco
    Song, Wenjie
    Mao, Meng
    Mygind, Per Holse
    Smith, Alden R.
    Chessler, Steven
    Komirenko, Allison S.
    Beckert, Michael
    Shu, Aimee D.
    Thornton, Paul S.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (07): : E2680 - E2689
  • [3] Adalimumab treatment maintainsn efficacy and safety in patients with ankylosing spondylits (AS)-2-year results from ATLAS
    van der Heijde, D.
    Schiff, M.
    Sieper, J.
    Kivitz, A.
    Dijkmans, B.
    Mease, P.
    Kupper, H.
    Wong, R.
    Davis, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 411 - 412
  • [4] Efficacy and safety of collagenase treatment for Dupuytren's disease: 2-year follow-up results
    Van Beeck, A.
    Van den Broek, M.
    Michielsen, M.
    Didden, K.
    Vuylsteke, K.
    Verstreken, F.
    HAND SURGERY & REHABILITATION, 2017, 36 (05): : 346 - 349
  • [5] Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials
    Lebwohl, Mark
    Warren, Richard B.
    Sofen, Howard
    Imafuku, Shinichi
    Paul, Carle
    Szepietowski, Jacek C.
    Spelman, Lynda
    Passeron, Thierry
    Vritzali, Eleni
    Napoli, Andrew
    Kisa, Renata M.
    Buck, Alex
    Banerjee, Subhashis
    Thaci, Diamant
    Blauvelt, Andrew
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (05) : 668 - 679
  • [6] Adalimumab treatment maintains efficacy and safety in patients with ankylosing spondylitis (AS)-2-year results from ATLAS
    van der Heijde, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 412 - 412
  • [7] Efficacy and safety of lurasidone in adolescents with schizophrenia: Results of a 2-year, open-label extension study
    Goldman, R.
    Correll, C.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Loebel, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S88 - S89
  • [8] Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
    Mease, Philip J.
    Merola, Joseph F.
    Tanaka, Yoshiya
    Gossec, Laure
    Mcinnes, Iain B.
    Ritchlin, Christopher T.
    Landewe, Robert B. M.
    Asahina, Akihiko
    Ink, Barbara
    Heinrichs, Andrea
    Bajracharya, Rajan
    Shende, Vishvesh
    Coarse, Jason
    Coates, Laura C.
    RHEUMATOLOGY AND THERAPY, 2024, 11 (05) : 1363 - 1382
  • [9] 2-year efficacy and safety results of the French experiment on cannabis for medical use in painful spasticity in multiple sclerosis
    Durand-Dubief, Francoise
    Thouvenot, Eric
    Donze, Cecile
    Moreau, Thibault
    Dalliere, Clarisse Carra
    Lebrun-Frenay, Christine
    Authier, Nicolas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1123 - 1124
  • [10] Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results
    Zhang, Hong
    Lafayette, Richard
    Wang, Bei
    Ying, Lisa
    Zhu, Zhengying
    Stone, Andrew
    Kristensen, Jens
    Barratt, Jonathan
    KIDNEY360, 2024, 5 (12): : 1881 - 1892
12345